Ligand proposes $550M convertible notes due 2031; amends credit facility covenants

LIGAND PHARMACEUTICALS INC

Proposes $550M aggregate principal of convertible senior notes due 2031; additional $82.5M option granted to initial purchasers.
Net proceeds to fund convertible note hedge costs, up to $75M share repurchase, and general corporate purposes including Xoma acquisition.
Enters convertible note hedge and warrant transactions to reduce potential dilution from note conversion.
Fourth Amendment to credit agreement sets minimum EBITDA at $100M for periods ending June 30, 2026 through March 31, 2027, then $150M.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

LIGAND PHARMACEUTICALS INC amended Fourth Amendment with Citibank, N.A., as Administrative Agent (effective 2026-06-22).

Action: amendment
Agreement: credit facility
Counterparty: Citibank, N.A., as Administrative Agent
Effective: 2026-06-22

Exact text from the filing

on June 22, 2026, Ligand Pharmaceuticals Incorporated (the “Company”), as borrower, entered into a Consent and Fourth Amendment to Credit Agreement (the “Fourth Amendment”) with certain of the Company’s subsidiaries, as Guarantors (as defined therein), the Lenders (as defined therein) party thereto, and Citibank, N.A., as Administrative Agent (as defined therein)

View on SEC.gov

627 material agreements filed in the last 30 days. Browse all material agreements →

LIGAND PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001193125-26-276694

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.